WO2015006999A1 - Noyau de blocage lacrymal ductile - Google Patents

Noyau de blocage lacrymal ductile Download PDF

Info

Publication number
WO2015006999A1
WO2015006999A1 PCT/CN2013/080552 CN2013080552W WO2015006999A1 WO 2015006999 A1 WO2015006999 A1 WO 2015006999A1 CN 2013080552 W CN2013080552 W CN 2013080552W WO 2015006999 A1 WO2015006999 A1 WO 2015006999A1
Authority
WO
WIPO (PCT)
Prior art keywords
core
lacrimal
tube
tube body
diameter
Prior art date
Application number
PCT/CN2013/080552
Other languages
English (en)
Chinese (zh)
Inventor
高前应
李玉洁
Original Assignee
广州卫视博生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广州卫视博生物科技有限公司 filed Critical 广州卫视博生物科技有限公司
Publication of WO2015006999A1 publication Critical patent/WO2015006999A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/007—Methods or devices for eye surgery
    • A61F9/00772—Apparatus for restoration of tear ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12099—Occluding by internal devices, e.g. balloons or releasable wires characterised by the location of the occluder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12131—Occluding by internal devices, e.g. balloons or releasable wires characterised by the type of occluding device
    • A61B17/12159—Solid plugs; being solid before insertion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/12—Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels, umbilical cord
    • A61B17/12022—Occluding by internal devices, e.g. balloons or releasable wires
    • A61B17/12027—Type of occlusion
    • A61B17/12036—Type of occlusion partial occlusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831—Material properties
    • A61B2017/0084—Material properties low friction
    • A61B2017/00849—Material properties low friction with respect to tissue, e.g. hollow organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
    • A61B2017/00831—Material properties
    • A61B2017/00893—Material properties pharmaceutically effective

Definitions

  • the invention relates to the technical field of medical instruments, in particular to a lacrimal canal core for treating dry eye and preventing narrowing of lacrimal passage after acid-base burn.
  • Dry eye syndrome refers to symptoms such as decreased tears or decreased function of lacrimal glands causing dry eyes, acid eyes, itchy eyes, photophobia, and decreased vision. It damages the cornea and, in severe cases, corneal softening and perforation.
  • the current important method for treating dry eye syndrome is puncture embolization.
  • the method is to seal the tear exclusion tube by implanting a lacrimal duct embolization.
  • the method preserves the natural tears secreted by the lacrimal passage itself and prolongs the time the tears stay on the surface of the eye.
  • neither degradable nor permanent lacrimal plugs can treat dry eye.
  • the present invention overcomes the defects of the prior art and provides a lacrimal tube obstruction core, which can not only treat dry eye disease conveniently, safely and stably, but also prevent narrowing of the lacrimal passage after acid-base burn.
  • a tear tube small core comprising a core tube, the core tube has a tapered tip at one end, and the other end of the core tube has a core end.
  • the head end of the core block has a flat cylindrical shape without an angular shape, and the head end has no angular angle, and the degree of damage to the eye tissue is low.
  • the core tube body has a length of 2-20 mm, the diameter of the core tube body is 0.1 to 1 mm, the thickness of the core end of the resistor core is 0.1 to 1 mm, and the diameter of the head end of the resistor core is 0.5 to 1.5 mm. It is suitable for the treatment of lacrimal passages of different patients, and the core tube is long enough. After entering the lacrimal duct, the shape can be deformed with the curvature of the lacrimal duct. Therefore, the tear tube has a strong contact with the lacrimal duct, and thus does not slip into tears. The road is also not easy to blink and fall out, and the position is fixed for a long time.
  • the core tube has a length of 4 to 16 mm, the diameter of the core tube is 0.3 to 0.8 mm, the thickness of the core end of the core is 0.3 to 0.8 mm, and the diameter of the head end of the core is 0.7 to 1.0 mm.
  • the core tube body and the core end of the core are processed by a medical silica gel material or processed by a polyolefin or a polyester medical polymer material, and the material is non-sticky to the nascent cells and can maintain the lacrimal passage.
  • the shape enters, therefore, the proliferating tissue cells after acid-base burn do not adhere to the lacrimal tube and prevent the narrowing of the lacrimal duct.
  • the tear-throat block of the material can adsorb drugs and nutritional factors, drugs and Nutritional factors can be applied to the surface of the lacrimal canal, so the effect of treating dry eye is particularly significant.
  • the core tube is provided with a cavity, a micro hole is arranged in the core tube body, and a drug or a nutrient factor is placed in the cavity, and the micro hole can be slowly released and then used by the eye. Absorption, can better treat eye acid and alkali burn symptoms and dry eye syndrome.
  • the tapered tip has a hollow structure
  • the head of the tapered tip is blunt and has an opening
  • the core tube body and the head end of the resistance core have a hollow structure
  • the tear tube is blocked.
  • the hollow tube of the tear duct adopts a hollow structure in order to allow excess tear fluid to flow out of the eye through the hollow structure of the tear duct and prevent the tears in the lacrimal duct from being moderate.
  • FIG. 1 is a schematic structural view of a tear canal core of the present invention
  • Figure 2 is a side view of Figure 1
  • 3 is a schematic structural view of a tear tube small core according to Embodiment 1 of the present invention
  • 4 is a schematic structural view of a tear canal core of the second embodiment of the present invention.
  • a lacrimal canal core comprises a core preventing tube body 1 having a tapered tip 3 at one end, and the other end of the core preventing tube body 1 has a core preventing head. End 2.
  • the head end 2 of the core block has a flat cylindrical shape without an angular shape, and the end portion 2 of the core block has no angular shape, and the degree of damage to the eye tissue cells is low.
  • the dry eye When the tear canal of the structure is implanted into the lacrimal duct, the dry eye can be treated conveniently, safely and stably, and the lacrimal passage can be prevented from narrowing after the acid-base burn, and since it has a head end, it can be conveniently
  • the tweezers are removed or implanted into the lacrimal passage. Since the core tube 1 is long enough to be deformed after the lacrimal passage is implanted, the shape of the lacrimal tube is deformed by the curvature of the lacrimal duct, so that the lacrimal tube is in firm contact with the lacrimal passage, and thus does not slide down to the lacrimal passage, and is not easily blinked. Out, the position is fixed for a long time.
  • the size of the tear tube is suitable for treating different patients:
  • the core tube body 1 has a length of 2 mm, the core tube body 1 has a diameter of 0.1 mm, the core end portion 2 has a thickness of 0.1 mm, and the core end portion 2 has a diameter of 0.5 mm.
  • a patient with dry eye syndrome recovers 28 days after using a tear tube of this size every day.
  • the core tube body 1 has a length of 4 mm, the core tube body 1 has a diameter of 0.3 mm, the core end portion 2 has a thickness of 0.3 mm, and the core end portion 2 has a diameter of 0.7 mm.
  • Patients with dry eye syndrome B recovered 33 days after using the tear tube of this size every day.
  • the core tube body 1 has a length of 8 mm, the core tube body 1 has a diameter of 0.5 mm, the core end portion 2 has a thickness of 0.5 mm, and the core end portion 2 has a diameter of 0.9 mm.
  • Patients with dry eye syndrome were rehabilitated 32 days after using a small size of this class of tear ducts.
  • the core tube body 1 has a length of 10 mm, the core tube body 1 has a diameter of 0.8 mm, the core end portion 2 has a thickness of 0.8 mm, and the core end portion 2 has a diameter of 1.2 mm.
  • the patient is rehabilitated for 36 days after using the tear tube of this size every day.
  • the patient who is burned by acid and alkali burns the core of the tear tube with this size every day.
  • the preventive effect is good and the lacrimal duct is not narrowed. , 96 days of rehabilitation.
  • the core tube body 1 has a length of 16 mm, the core tube body 1 has a diameter of 0.9 mm, the core end portion 2 has a thickness of 0.9 mm, and the core end portion 2 has a diameter of 1.3 mm.
  • Patients with dry eye syndrome have used this type of tear tube to prevent core, and recovered for 40 days.
  • Patients with acid-base burns use the tear tube of this size every day.
  • the preventive effect is good and the lacrimal duct is not narrowed. , 98 days of recovery.
  • the core tube body 1 has a length of 20 mm, the core tube body 1 has a diameter of 1 mm, the core end portion 2 has a thickness of 1 mm, and the core end portion 2 has a diameter of 1.5 mm.
  • Patients with dry eye syndrome use 37-day rehabilitated tears of the small size of the tear tube after daily use.
  • Patients with acid-base burns use the tear ducts of this size every day. The preventive effect is good and the lacrimal passage is not narrowed. , 100 days of recovery.
  • the length of the core tube is 2-8 mm, it is effective as a treatment for dry eye, and is not suitable for preventing narrowing of the lacrimal passage after acid-base burn.
  • the length of the core tube is 8-20 mm, it can be used to treat dry eye and prevent narrowing of the lacrimal passage after acid-base burn.
  • the core tube body 1 and the core end 2 of the invention are processed by a medical silica gel material or processed by a polyolefin or a polyester medical polymer material, and the material is non-sticky to the new cells, Maintaining the shape of the lacrimal duct, therefore, the proliferating tissue cells after acid-base burn do not adhere to the lacrimal tube and prevent the narrowing of the lacrimal duct.
  • the tear-tube-resistance of the material can adsorb drugs and nutritional factors. Drugs and trophic factors can be applied to the surface of the lacrimal canal, so the effect of treating dry eye is particularly significant.
  • Embodiment 1 as shown in FIG. 3, the core tube body 1 is provided with a cavity 5, and the core tube body 1 is provided with a micro hole 4 through the core end 2 to the cavity 5 Injecting drugs or nutrient factors, etc., drugs or nutrient factors are slowly absorbed into the lacrimal passage through the micropores 4 and absorbed by the eyes, which can better treat the symptoms of acid-base burns and dry eye in the eyes.
  • the tapered tip 3 has a hollow structure
  • the head of the tapered tip 3 is blunt and has an opening
  • the core tube body 1 and the core end 2 They all have a hollow structure, and the tear canal is prevented from being inserted into the core.
  • the hollow structure of the tear tube is designed to allow excess tears to flow out of the eye through the hollow structure of the tear canal, keeping the tears in the eye moderate and treating dry eyes. The effect of the disease is significant.

Landscapes

  • Health & Medical Sciences (AREA)
  • Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Plastic & Reconstructive Surgery (AREA)
  • Prostheses (AREA)

Abstract

La présente invention concerne un noyau de blocage lacrymal ductile qui comprend un corps tubulaire de noyau de blocage (1). Une extrémité du corps tubulaire de noyau de blocage (1) est dotée d'une pointe de forme conique (3), et l'autre de ses extrémités est dotée d'une extrémité tête de noyau de blocage (2). Le noyau de blocage lacrymal ductile peut non seulement être utilisé pour traiter convenablement et en toute sécurité la xérophtalmie, mais peut également empêcher le rétrécissement du canal lacrymal après des brûlures par un acide ou un alcalin, et l'extrémité tête de noyau de bocage (2) peut être retirée des voies lacrymales ou implantée dans ces dernières commodément à l'aide de pinces.
PCT/CN2013/080552 2013-07-15 2013-07-31 Noyau de blocage lacrymal ductile WO2015006999A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2013103042139A CN103349588A (zh) 2013-07-15 2013-07-15 泪小管阻芯
CN201310304213.9 2013-07-15

Publications (1)

Publication Number Publication Date
WO2015006999A1 true WO2015006999A1 (fr) 2015-01-22

Family

ID=49306075

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2013/080552 WO2015006999A1 (fr) 2013-07-15 2013-07-31 Noyau de blocage lacrymal ductile
PCT/CN2014/080700 WO2015007139A1 (fr) 2013-07-15 2014-06-25 Cœur de barrière canaliculaire

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/080700 WO2015007139A1 (fr) 2013-07-15 2014-06-25 Cœur de barrière canaliculaire

Country Status (2)

Country Link
CN (3) CN103349588A (fr)
WO (2) WO2015006999A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106667656A (zh) * 2016-06-30 2017-05-17 广州聚明生物科技有限公司 生物可降解泪道栓及其制备方法和应用
WO2022055825A1 (fr) * 2020-09-10 2022-03-17 Oasis Medical, Inc. Dispositifs et procédés pour occlure une ouverture méatique

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103349588A (zh) * 2013-07-15 2013-10-16 广州卫视博生物科技有限公司 泪小管阻芯
CN104984410A (zh) * 2015-07-29 2015-10-21 陕西博与再生医学有限公司 一种降解可控的泪道栓及其制备方法
CN106344257B (zh) * 2016-08-31 2018-07-10 李志强 一种栓体规模可调的泪道栓
CN106491270B (zh) * 2016-12-23 2018-08-14 中国医科大学附属第一医院 一种泪点扩张装置
CN110711075A (zh) * 2018-07-11 2020-01-21 吴坚 一种泪小管栓塞

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
CN102112076A (zh) * 2007-09-07 2011-06-29 Qlt栓塞输送公司 泪腺植入物及相关方法
US20120059338A1 (en) * 2010-09-08 2012-03-08 Beeley Nathan R F Punctal plug containing drug formulation
CN102688080A (zh) * 2012-06-05 2012-09-26 杭州柳茶医药科技有限公司 一种自动调节泪量的鼻泪管栓塞体及与其配套的安放工具
CN102860901A (zh) * 2006-06-21 2013-01-09 庄臣及庄臣视力保护公司 用于递送活性试剂的泪点塞

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2834446B1 (fr) * 2002-01-08 2004-02-13 Ioltechnologie Production Clou meatique a expansion
CN100502956C (zh) * 2006-01-05 2009-06-24 天津市贝亿生物制品有限公司 用于泪管栓塞的胶原短棒
CN201108670Y (zh) * 2007-11-19 2008-09-03 丁明红 治疗慢性泪囊炎的疏通导管
CN104825270B (zh) * 2008-02-18 2017-10-24 马缇医疗股份有限公司 泪管植入物及相关方法
CN202505577U (zh) * 2012-04-09 2012-10-31 王秀丽 可吸收微渗透泪小点栓子及其安装工具
CN202875597U (zh) * 2012-09-10 2013-04-17 高传友 一种治疗眼病的放置在泪道内的泪道棒
CN103349588A (zh) * 2013-07-15 2013-10-16 广州卫视博生物科技有限公司 泪小管阻芯

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516522A (en) * 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
CN102860901A (zh) * 2006-06-21 2013-01-09 庄臣及庄臣视力保护公司 用于递送活性试剂的泪点塞
CN102112076A (zh) * 2007-09-07 2011-06-29 Qlt栓塞输送公司 泪腺植入物及相关方法
US20120059338A1 (en) * 2010-09-08 2012-03-08 Beeley Nathan R F Punctal plug containing drug formulation
CN102688080A (zh) * 2012-06-05 2012-09-26 杭州柳茶医药科技有限公司 一种自动调节泪量的鼻泪管栓塞体及与其配套的安放工具

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106667656A (zh) * 2016-06-30 2017-05-17 广州聚明生物科技有限公司 生物可降解泪道栓及其制备方法和应用
WO2022055825A1 (fr) * 2020-09-10 2022-03-17 Oasis Medical, Inc. Dispositifs et procédés pour occlure une ouverture méatique

Also Published As

Publication number Publication date
CN103876887A (zh) 2014-06-25
CN203915219U (zh) 2014-11-05
WO2015007139A1 (fr) 2015-01-22
CN103349588A (zh) 2013-10-16

Similar Documents

Publication Publication Date Title
WO2015006999A1 (fr) Noyau de blocage lacrymal ductile
ES2926786T3 (es) Tubo de timpanostomía de una etapa
CA2265091A1 (fr) Dispositif d'intubation du canal de drainage lacrymal
JP2008061983A (ja) 鼓膜ドレーンチューブ
ES2836219T3 (es) Aguja para recoger ovocitos
CN203154060U (zh) 一种泪道探查及治疗装置
Mudry The tympanostomy tube: an ingenious invention of the mid 19th century
JP2005110765A (ja) 涙点プラグセット
US20140201966A1 (en) Device and method for automatically weaving seal segments
CN204208094U (zh) 咽鼓管检查治疗装置
CN104490499B (zh) 一种记忆合金五官腔道支架
CN205126802U (zh) 中医温针防护装置
JPWO2005082303A1 (ja) 埋め込み式人工耳管
CN205434661U (zh) 一种泪道引流器
JP5992922B2 (ja) 耳管鼓膜チューブ
CN210170649U (zh) 泪道引流管防脱落盘及其内置结构
KR200488434Y1 (ko) 중이염 환기관
CN206063539U (zh) 新型医用经口咽鼓管球囊扩张导管专用置入器械
CN211633870U (zh) 勾型泪道管
CN202605094U (zh) 止鼾器
Cherecheanu et al. Lacrimal Stents and Intubation Systems–our expertise
CN217286298U (zh) 鼓膜置管器
RU76221U1 (ru) Устройство для лечения заболеваний уха
CN203341912U (zh) 带吸引管的耳用膝状镊
CN108852614B (zh) 泪小管栓塞推注器

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13889425

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 30.05.2016)

122 Ep: pct application non-entry in european phase

Ref document number: 13889425

Country of ref document: EP

Kind code of ref document: A1